Clinical cardiac safety profile of nilotinib.

ABSTRACT:

Background

Nilotinib is a second-generation tyrosine kinase inhibitor with significant efficacy as first- or second-line treatment in patients with chronic myeloid leukemia. Despite preclinical evidence indicating a risk of prolongation of the QT interval, which was confirmed in clinical trials, detailed information on nilotinib's cardiac safety profile is lacking.

Design and methods

Here, we retrospectively assessed cardiovascular risk factors in 81 patients who were being or had previously been treated with nilotinib therapy and evaluated cardiovascular parameters by longitudinal monitoring of the QT interval and left ventricular ejection fraction. Detailed information on the occurrence and management of defined cardiac adverse events was extracted.

Results

The medi

SUBMITTER: Kim TD 

PROVIDER: S-EPMC3366654 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature